Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Fred Poordad

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Clinics in Liver Disease|October 16, 2004
Liver transplant and recurrent diseaseF Fred Poordad
Journal of Clinical Gastroenterology|October 20, 2004
The role of leptin in NAFLD: contender or pretender?F Fred Poordad
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2004
IDN-6556 Idun Pharmaceuticals IncF Fred Poordad
Expert Opinion on Emerging Drugs|August 9, 2005
Nonalcoholic fatty liver disease: a reviewF Fred Poordad
Expert Opinion on Emerging Drugs|June 7, 2005
Therapeutic strategies in nonalcoholic fatty liver disordersF Fred Poordad
Expert Review of Molecular Diagnostics|September 7, 2004
FIBROSpect II: a potential noninvasive test to assess hepatic fibrosisF Fred Poordad
Antiviral Therapy|May 29, 2009
Virological relapse in chronic hepatitis CF Fred Poordad, Steven L Flamm
Expert Opinion on Emerging Drugs|November 13, 2003
Developments in hepatitis C therapy during 2000-2002F Fred Poordad, Tram Tran, Paul Martin
Hepatology (Baltimore, Md.)|June 27, 2002
Hepatitis C infection and the patient with end-stage renal diseaseFabrizio Fabrizi, F Fred Poordad, Paul Martin
Journal of Managed Care Pharmacy : JMCP|October 1, 2005
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis CDaniel C Malone, Tram T Tran, F Fred Poordad
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Clinics in Liver Disease|October 16, 2004
Liver transplant and recurrent diseaseF Fred Poordad
Journal of Clinical Gastroenterology|October 20, 2004
The role of leptin in NAFLD: contender or pretender?F Fred Poordad
Current Opinion in Investigational Drugs (London, England : 2000)|December 3, 2004
IDN-6556 Idun Pharmaceuticals IncF Fred Poordad
Expert Opinion on Emerging Drugs|August 9, 2005
Nonalcoholic fatty liver disease: a reviewF Fred Poordad
Expert Opinion on Emerging Drugs|June 7, 2005
Therapeutic strategies in nonalcoholic fatty liver disordersF Fred Poordad
Expert Review of Molecular Diagnostics|September 7, 2004
FIBROSpect II: a potential noninvasive test to assess hepatic fibrosisF Fred Poordad
Antiviral Therapy|May 29, 2009
Virological relapse in chronic hepatitis CF Fred Poordad, Steven L Flamm
Expert Opinion on Emerging Drugs|November 13, 2003
Developments in hepatitis C therapy during 2000-2002F Fred Poordad, Tram Tran, Paul Martin
Hepatology (Baltimore, Md.)|June 27, 2002
Hepatitis C infection and the patient with end-stage renal diseaseFabrizio Fabrizi, F Fred Poordad, Paul Martin
Journal of Managed Care Pharmacy : JMCP|October 1, 2005
Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis CDaniel C Malone, Tram T Tran, F Fred Poordad
Pageof 2